MedTrace Logo

Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis

NCT00497952 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2023-10-12

No results posted yet for this study

Summary

The goal of this research study is to establish chimerism with the goal to halt disease progression in patients with Multiple Sclerosis.

Conditions

Interventions

BIOLOGICAL

hematopoetic stem cell infusion

Enriched hematopoietic stem cell infusion

Sponsors & Collaborators

  • Talaris Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Suzanne T Ildstad, MD · Talaris Therapeutics Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2024-12-31
Completion
2024-12-31
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00497952 on ClinicalTrials.gov